Medivir has completed a successful pre-IND meeting with the FDA
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
0,640€
-3,90%
Echtzeit-Aktienkurs MEDIVIR AB
Bid:
Ask:
Nachrichten zur MEDIVIR AB Aktie
Medivir to present at the Erik Penser Bank Healthcare Day
STOCKHOLM, Nov. 29, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Medivir to present at the Erik Penser Bank Healthcare Day
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Medivir appoints ex-AstraZeneca cancer drug exec as chief medical officer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Medivir recruits Pia Baumann as new Chief Medical Officer
STOCKHOLM, Nov. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Medivir recruits Pia Baumann as new Chief Medical Officer
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Medivir to present at the Redeye Life Science Day
STOCKHOLM, Nov. 16, 2022 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Medivir to present at the Redeye Life Science Day
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference
STOCKHOLM, Nov. 9, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Medivir AB GAAP EPS of -SEK 0.27, revenue of SEK 1.1M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2022
STOCKHOLM, Nov. 3, 2022 /PRNewswire/ -- The measures to increase the pace of patient recruitment have yielded results. The Fostrox…
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2022
The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected.
July…
Nomination Committee of Medivir appointed
STOCKHOLM, Oct. 28, 2022 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) today announces that the nomination committee now has…
Nomination Committee of Medivir appointed
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of…